We’re thrilled to announce the closing of our merger with Choice Pharma, a Pan-Asian contract research organization. The merger significantly strengthens our operational and therapeutic expertise in Asia—a region in high demand by our clients.

In addition, we have extended our global footprint to include 20 offices in 15 countries with new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.

Jeff Williams, CEO, commented: “In order to continue to address the changing industry landscape and the high demand by clients for operations in Asia, we began the process of determining the best path for investing in the growth of our company, which led us to Choice Pharma. With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides.”

Together, Clinipace will now be home to more than 640 global employees. Combined, we have managed over 1,500 clinical research studies and 300+ completed regulatory and strategic development engagements.

To read today’s announcement, click here.